Genomes and Genes
Summary: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Publications247 found, 100 shown here
- Intravenous immunoglobulins in the treatment of dengue illnessSenaka Rajapakse
Faculty of Medicine, University of Colombo, Colombo 8, Sri Lanka
Trans R Soc Trop Med Hyg 103:867-70. 2009..manifestations of severe dengue together with the potentially beneficial immunomodulatory effects of intravenous immunoglobulins (IVIG) suggest a possible place for treatment with this expensive therapy...
- Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart AssociationJane W Newburger
Circulation 110:2747-71. 2004..Coronary artery aneurysms or ectasia develop in approximately 15% to 25% of untreated children and may lead to ischemic heart disease or sudden death...
- Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylationYoshikatsu Kaneko
Laboratory of Molecular Genetics and Immunology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
Science 313:670-3. 2006..This differential sialylation may provide a switch from innate anti-inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge...
- Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's diseaseR C Dodel
Department of Neurology, Friedrich Wilhelms University, Sigmund Freudstr 25, 53105 Bonn, Germany
J Neurol Neurosurg Psychiatry 75:1472-4. 2004..This study reports the results from a pilot study using IVIgG in patients with AD...
- Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cellsThanyalak Tha-In
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Transplantation 89:1446-55. 2010b>Intravenous immunoglobulins (IVIg) therapy is effective as a treatment for T-cell-mediated immune diseases, but whether and how IVIg suppress allogeneic T-cell responses is largely unknown.
- Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptideGili Istrin
Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
J Neurosci Res 84:434-43. 2006..Thus, several mechanisms can be considered when examining the effects of IVIg. Our work supports the hypothesis that IVIg interferes by more than one mechanism in clearing AbetaP from the brains of Alzheimer's patients...
- Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in miceDavid Ben-Nathan
Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
J Infect Dis 188:5-12. 2003..These results indicate that antibodies play a major role in protection and recovery from WNV infection and that IVIG can be used as first-line therapy...
- Clinical uses of intravenous immunoglobulinS Jolles
Department of Clinical Immunology, Royal Free Hospital London, UK
Clin Exp Immunol 142:1-11. 2005
- Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndromeDonato Rigante
Department of Pediatric Sciences, Universita Cattolica Sacro Cuore, Largo A Gemelli, 8, 00168, Rome, Italy
Rheumatol Int 30:841-6. 2010Clues to predict the response to intravenous immunoglobulins (IVIG) and the development of coronary artery abnormalities (CAA) in children with Kawasaki syndrome (KS) are still undefined...
- Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitroA Pollreisz
Department of Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
Br J Dermatol 159:578-84. 2008b>Intravenous immunoglobulins (IVIg) and cytomegalovirus immunoglobulins (CMVIg) are currently finding increased acceptance in clinical states of high immune activity and in transplant recipients...
- Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseasesMartine Bruley-Rosset
Laboratoire Francais du Fractionnement et des Biotechnologies, Les Ulis, France
Lab Invest 83:1013-23. 2003b>Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human polyclonal Ig G (IgG) that exert immunomodulatory effects in patients with autoimmune or systemic inflammatory diseases...
- Immunoglobulin failure and retreatment in Kawasaki diseaseK Durongpisitkul
Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Prannok Road, Bangkok, Thailand 10700
Pediatr Cardiol 24:145-8. 2003..6% of our Kawasaki patients. We found that low hemoglobin (<10 G/DL), high neutrophil count (> 75%), high band count, and a low albumin were associated with the requirement for retreatment with a second dose of IVIG...
- Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki diseaseChih Lu Wang
Division of Allergy and Immunology, Chang Gung Children s Hospital at Kaohsiung, Chang Gung University, Niau Sung, Kaohsiung, Taiwan
Pediatrics 111:E140-7. 2003..Kawasaki disease (KD) is an acute febrile vasculitic syndrome in children. CD40 ligand (CD40L) has been implicated in certain types of vasculitis. We proposed that CD40L expression might be correlated with coronary artery lesions in KD...
- Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expressionNadine Pigard
BMT Research GmbH, Vienna, Austria
J Neuroimmunol 209:114-20. 2009..We suggest that the modulation of chemokine expression in peripheral T cells contributes to the beneficial activity of IVIG in patients with MS exacerbation...
- 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer diseaseNorman R Relkin
Department of Neurology, the Weill Cornell Medical College, New York, NY, USA
Neurobiol Aging 30:1728-36. 2009..Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol...
- Smallpox vaccination and adverse reactions. Guidance for cliniciansJoanne Cono
Bioterrorism Preparedness and Response Program, National Center for Infectious Diseases, USA
MMWR Recomm Rep 52:1-28. 2003..asp. Physicians at military medical facilities can request VIG or cidofovir by calling the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at 301-619-2257 or 888-USA-RIID...
- Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disordersP Imbach
Pediatric Hematology Oncology, University Children s Hospital, Medical Faculty of University of Basel, Basel, Switzerland
Vox Sang 98:385-94. 2010..Controlled clinical and laboratory studies may follow based on new, validated patient selection criteria and focused on mechanisms of action, leading to more evidence-based indications...
- S100A12 (EN-RAGE) in monitoring Kawasaki diseaseDirk Foell
Department of Paediatrics, University Hospital Munster, Von Esmarch Str 58, 48149, Munster, Germany
Lancet 361:1270-2. 2003..0001). Since the interaction of S100A12 with multiligand receptors has a key role in inflammatory responses, this protein could serve as a novel target for future therapeutic interventions in inflammatory disorders...
- Intravenous immunoglobulins--understanding properties and mechanismsA Durandy
Inserm U768, Universite Paris Descartes, Hospital Necker, Paris, France
Clin Exp Immunol 158:2-13. 2009..These findings demonstrate the considerable progress that has been made in understanding the mechanisms of action of IVIgs, and may influence future perspectives in the field of Ig therapy...
- Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulinsWillem F M Arts
Department of Paediatric Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Epilepsia 50:55-8. 2009..It might also reflect the natural course of the disease. Although the temporal relation between IVIg treatment and clinical improvement cannot be denied in individual patients, its real value remains to be determined...
- Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitisA Hamdan
Internal Medicine B, Rabin Medical Center, Beilinson Campus, Petach Tikva 49100, Israel
Transpl Infect Dis 4:160-2. 2002..This is the second case of an immunosuppressed patient responding to the same preparation of intravenous immunoglobulins. Larger studies are required in order to establish the therapeutic role of immunoglobulins in patients ..
- Resistance to intravenous immunoglobulin in children with Kawasaki diseaseAdriana H Tremoulet
Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital San Diego, San Diego, CA, USA
J Pediatr 153:117-21. 2008..To explore the increased incidence of intravenous immunoglobulin- (IVIG) resistance among San Diego County patients with Kawasaki disease (KD) in 2006 and to evaluate a scoring system to predict IVIG-resistant patients with KD...
- Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurologyH P Hartung
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Clin Exp Immunol 158:23-33. 2009..This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact...
- Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki diseaseM W Quasney
Division of Critical Care, Department of Pediatrics, Crippled Children s Foundation Research Center, LeBonheur Children s Medical Center, University of Tennessee, Memphis, Tennessee 38103, USA
Pediatr Res 49:686-90. 2001..The increased frequency of the high secretor alleles in white children with KD suggests that these loci may be related to susceptibility to KD and to outcome after disease...
- Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseasesNing Li
Department of Dermatology, University of North Carolina at Chapel Hill, North Carolina 27599, USA
J Clin Invest 115:3440-50. 2005..These data demonstrate that the therapeutic efficacy of HDIG treatment in the pemphigus and pemphigoid models is dependent on FcRn. Thus, FcRn is a promising therapeutic target for treating such IgG-mediated autoimmune diseases...
- Evidence for the use of intravenous immunoglobulins--a review of the literatureShaye Kivity
Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
Clin Rev Allergy Immunol 38:201-69. 2010b>Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies...
- Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study GroupJ C Burns
Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla 92093 0830, USA
Pediatr Infect Dis J 17:1144-8. 1998..To determine the prevalence and outcome of intravenous gamma-globulin (IVIG) retreatment in patients with Kawasaki disease (KD)...
- Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiencyJavier De Gracia
Department of Pneumology, Hospital Universitari Vall d Hebron, Roger de Flor 235 bajos 2 a, 08025 Barcelona, Spain
Int Immunopharmacol 4:745-53. 2004..Lung damage progression is the most frequent condition in patients with common variable immunodeficiency (CVID). Appropriate immunoglobulin dose adjustments and follow-up guidelines to evaluate this have not been well established...
- No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexyPhilipp O Valko
Department of Neurology, University Hospital of Zurich, Frauenklinikstrasse 26, Zurich, Switzerland
J Neurol 255:1900-3. 2008We report on four patients with narcolepsy with cataplexy (NC), who were treated with high-dose intravenous immunoglobulins (IVIg)...
- Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgGMarie Joëlle de Grandmont
HEMA QUEBEC, Recherche et Developpement, Sainte Foy, Quebec, Canada
Blood 101:3065-73. 2003The therapeutic effects of intravenous immunoglobulins (IVIGs) in several autoimmune diseases are characterized by a decrease in pathologic autoantibody levels...
- Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiencyPaula Jane Busse
Division of Clinical Immunology, Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
J Allergy Clin Immunol 109:1001-4. 2002..The standard treatment, intravenous immunoglobulin (IVIG), has been available for the past 20 years. No large-scale study has compared the incidence of pneumonia in these patients before and after IVIG treatment...
- Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)Mamoru Ayusawa
Department of Pediatrics, Nihon University School of Medicine, Tokyo 173 8610, Japan
Pediatr Int 47:232-4. 2005..Major alterations are interpretation of cases with 4 or fewer febrile days shortened by early intravenous immunoglobulin treatment, and the clinical importance of atypical (incomplete, or suspected) cases...
- Serum alanine aminotransferase concentrations in patients with Kawasaki diseaseRitei Uehara
Department of Public Health, Jichi Medical School, 3311 1 Yakushiji Minamikawachi, Tochigi 329 0498, Japan
Pediatr Infect Dis J 22:839-42. 2003
- Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosisAles Dudesek
Department of Neurology, University of Rostock, Gehlsheimer Str 20, 18147, Rostock, Germany
J Neurol 253:V50-8. 2006..As recently shown IVIG administration right from the early weeks of pregnancy appears to be a promising strategy, but cannot be recommended from the viewpoint of evidence-based medicine...
- Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cellsThanyalak Tha-In
Department of Gastroenterology and Hepatology, Erasmus Medical Center University Medical Center, 3015 CE Rotterdam, The Netherlands
Blood 110:3253-62. 2007The modes of action of intravenous immunoglobulins (IVIgs) in exerting their immunomodulatory properties are broad and not fully understood...
- Predictive risk factors for coronary artery abnormalities in Kawasaki diseaseTaeyeun Kim
Department of Pediatrics, Korea University College of Medicine, Seoul, South Korea
Eur J Pediatr 166:421-5. 2007..Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA...
- Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexyRolf Fronczek
J Neurol 254:1607-8. 2007
- High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosusE Toubi
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel
Hum Immunol 66:395-402. 2005..However, this needs to be confirmed in double-blind, placebo-controlled studies...
- Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidenceRichard Dodel
Department of Neurology, Philipps University, Marburg, Germany
Drugs 70:513-28. 2010..Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the ..
- Multifocal motor neuropathyE Nobile-Orazio
Giorgio Spagnol Service of Clinical Neuroimmunology, Dino Ferrari Centre, Department of Neurological Sciences, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy
J Neuroimmunol 115:4-18. 2001..Even if many progresses have been made on the diagnosis and therapy of MMN, there are still several issues on the nosological position, etiopathogenesis and long-term treatment of this neuropathy that need to be clarified...
- Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentationEric Aubin
Department of Research and Development, HEMA QUEBEC, Quebec City, Canada
Blood 115:1727-34. 2010..Such inhibition of T-cell responses by reducing antigen presentation may therefore contribute to the well-known anti-inflammatory effects of IVIg in autoimmune diseases...
- Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathyK Kuitwaard
Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Neurol Neurosurg Psychiatry 81:1374-9. 2010..A liquid IVIg preparation is more user friendly and potentially can be infused at a faster rate...
- Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulinsTanja Kuhlmann
Department of Neuropathology, Charite, Humboldt Universitat, Berlin, Germany
J Neurosci Res 67:185-90. 2002..Additionally, the effects of intravenous immunoglobulins (IVIg) on this process were investigated...
- Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemiaJohannes N Hoffman
Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
Shock 29:133-9. 2008..Our findings can explain better efficacy of IgM-enriched Igs in patients with severe sepsis...
- High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulinsRoberto Perricone
Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
Am J Reprod Immunol 55:232-9. 2006To determine the levels of peripheral blood natural killer (NK) cells in healthy women and recurrent aborters, and the effect of intravenous immunoglobulins (IVIGs) on these levels.
- Thrombotic complications after intravenous immunoglobulin therapy in two patientsGeoffrey G Emerson
Wilmer Eye Institute, Johns Hopkins Medical Center, Baltimore, Maryland, USA
Pharmacotherapy 22:1638-41. 2002..We suggest that IVIg may promote thrombosis by increasing blood viscosity, activating platelets, or causing vasospasm and should be administered with caution...
- Cutaneous polyarteritis nodosa treated with intravenous immunoglobulinsI Lobo
J Eur Acad Dermatol Venereol 22:880-2. 2008
- Intravenous immunoglobulins, pregnancy and multiple sclerosisChristian Confavreux
European Database for Multiple Sclerosis EDMUS Coordinating Center, Service de Neurologie A, INSERM U433, Hopital Neurologique Pierre Wertheimer, Lyon, France
J Neurol 251:1138-9. 2004
- Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapyPeter Kubisz
National Hemostasis and Thrombosis Center, Clinic of Hematology and Transfusion Medicine, Jessenius Faculty of Medicine of the Comenius University, Faculty Hospital, Martin, Slovakia
Med Sci Monit 15:CS105-11. 2009..ITI eradicates FVIII inhibitors and allows retreatment with FVIII concentrates in 70% of patients...
- Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspectiveSophie Siberil
INSERM UMRS 872, Universite Rene Descartes Paris 5, Université Pierre et Marie Curie UPMC Paris 6 75006 Paris, France
Ann N Y Acad Sci 1110:497-506. 2007Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agents in autoimmune and inflammatory disorders...
- High-dose intravenous immunoglobulins for lupus nephritis--a salvage immunomodulationL Rauova
Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
Lupus 10:209-13. 2001..In this review, the clinical and adverse effects, and mechanism of action, with special emphasis on modulation, of idiotypic network is discussed...
- [Indications for intravenous immunoglobulins]Luc Mouthon
Universite Paris Descartes, Faculte de Medecine, Service de Médecine Interne et Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris
Presse Med 35:714-9. 2006b>Intravenous immunoglobulins (IgIV) are therapeutic preparations of polyclonal human IgG, obtained from a pool of plasma from more than 1000 healthy donors...
- Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki diseaseV E A Honkanen
Division of Rheumatology, Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada
Pediatr Cardiol 24:122-6. 2003..We could not distinguish a group at such a low risk that these patients could be left untreated. Young patients with low albumin run a very high risk for CALs...
- Intravenous immunoglobulins in the therapy of paraneoplastic neurological disordersF Blaes
Department of Neurology, University of the Saarland, Homburg, Germany
J Neurol 246:299-303. 1999..We treated four patients suffering from paraneoplastic neurological syndromes with intravenous immunoglobulins. All four had high titers of antineuronal antibodies in serum and CSF...
- Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopeniaRyan J Hansen
Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA
Blood 100:2087-93. 2002..This model of ITP will be useful for further investigations of IVIG mechanism of action and for development of new therapies for ITP...
- Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulinsIsabelle St-Amour
Department of Research and Development, HEMA QUEBEC, Quebec QC, Canada G1V 5C3
Clin Immunol 133:52-60. 2009....
- Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelinesM C Dalakas
Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 4N248, 10 Center Drive MSC 1382, Bethesda, Maryland 20892 1382, USA
Muscle Nerve 22:1479-97. 1999..Finally, safety issues, risk factors, adverse reactions, spurious results or serological tests, and practical guidelines associated with the administration of IVIg in the treatment of neuromuscular disorders are presented...
- Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki diseaseK Y Lee
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Acta Paediatr 91:164-7. 2002..Total cholesterol and triglyceride increased slightly after 7 d. A significant decrease in HDL-cholesterol and C-reactive protein was seen 2 h and 24 h after IVIG treatment...
- Intravenous immunoglobulins in peripheral neuropathy associated with vasculitisY Levy
Department of Medicine B and the Centre for Autoimmune Diseases, Sheba Medical Centre Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel
Ann Rheum Dis 62:1221-3. 2003..Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both...
- Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000)Kyung Yil Lee
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Pediatr Infect Dis J 23:52-5. 2004..We evaluated the epidemiology and a range of clinical characteristics in children with Kawasaki disease (KD) in one area of South Korea...
- Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot studyF Nacci
Department of Medicine and Surgery, University of Florence, Italy
Ann Rheum Dis 66:977-9. 2007In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of the hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc.
- Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulinsK Gourgiotou
Department of Dermatology, University of Athens, A Sygros Hospital, Greece
J Eur Acad Dermatol Venereol 16:77-80. 2002..The treatment was well tolerated and the results were satisfactory. It seems that IVIg, due to its possible immunomodulatory mode of action, can be an efficacious therapeutic agent in this rare autoimmune disease...
- Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg)Stephan von Gunten
Institute of Pathology, University Hospital Basel, Basel, Switzerland
Autoimmun Rev 7:453-6. 2008Human intravenous immunoglobulins (IVIg) contain natural autoantibodies against the inhibitory lectin-receptors Siglec-8 and Siglec-9. These two members of the Siglec family are known to mediate both inhibitory and death signals...
- Identification of a receptor required for the anti-inflammatory activity of IVIGRobert M Anthony
The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA
Proc Natl Acad Sci U S A 105:19571-8. 2008..These studies thus identify an antibody receptor specific for sialylated Fc, and present the initial step that is triggered by IVIG to suppress inflammation...
- IV immunoglobulin does not reverse established weakness in MSJ H Noseworthy
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
Neurology 55:1135-43. 2000..Immunoglobulin (Ig) administration induces remyelination in the Theiler's virus model of MS...
- A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritisJ H Noseworthy
Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Neurology 56:1514-22. 2001..To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON)...
- Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki diseaseTohru Kobayashi
Department of Pediatrics and Developmental Medicine, Gunma University Graduate School of Medicine, Gunma 377 8511, Japan
Circulation 113:2606-12. 2006..In the present study, we developed models to predict unresponsiveness to intravenous immunoglobulin (IVIG) in Kawasaki disease (KD)...
- Multifocal motor neuropathyJan Thies H van Asseldonk
Department of Clinical Neurophysiology, Neuromuscular Research Group, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Netherlands
Lancet Neurol 4:309-19. 2005....
- Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cellsVinayakumar Siragam
Canadian Blood Services, 1800 Alta Vista Drive, Ottawa, Ontario, K1G 4J5, Canada
Nat Med 12:688-92. 2006..In conclusion, the clinical effects of IVIg in ameliorating ITP seem to involve the acute interaction of IVIg with activating Fc gammaR on dendritic cells...
- Initial intravenous gammaglobulin treatment failure in Kawasaki diseaseC A Wallace
Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
Pediatrics 105:E78. 2000....
- Management of immune thrombocytopenic purpura in adultsRoberto Stasi
Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
Mayo Clin Proc 79:504-22. 2004..We describe a logical and structured approach to the clinical management of ITP in adults, based on a literature review and our personal experience...
- Infliximab as a novel therapy for refractory Kawasaki diseaseJennifer E Weiss
Division of Pediatric Cardiology, Department of Pediatrics, Schneider Children s Hospital, North Shore Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
J Rheumatol 31:808-10. 2004..v.IG and methylprednisolone, who was treated with infliximab. After the first dose he defervesced and his laboratory measures improved...
- Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literatureDavid Hefer
Department of Internal Medicine, St Luke s Roosevelt Hospital Center, 1000 Tenth Avenue, 10019, New York, NY, USA
Ann Hematol 83:661-5. 2004..Ten patients out of the 29 reported patients died from this serious complication. In our patient, spontaneous reperfusion occurred without any treatment and he had an uneventful outcome...
- Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled studyPieter J Hoekstra
Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
J Clin Psychiatry 65:537-42. 2004..No data are available on the effectiveness of intravenous immunoglobulins (IVIG) on tic severity in unselected tic disorder patients.
- Adverse effects of treatment with intravenous immunoglobulins for neurological diseasesMatthias Wittstock
Dept of Neurology, University of Rostock, Gehlsheimer Str 20, 18147, Rostock, Germany
J Neurol 253:V75-9. 2006Therapy with intravenous immunoglobulins (IVIg) is considered to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%...
- A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki diseaseTakaomi Minami
Department of Pediatrics, Wakayama Medical University, Wakayama, Japan
J Pediatr 147:78-83. 2005..To investigate whether reduced levels of plasma platelet-activating factor acetylhydrolase (PAF-AH) as a result of a genetic polymorphism are involved in the pathogenesis of Kawasaki disease (KD)...
- Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issuesRalf Gold
Department of Neurology at St Josef Hospital, University of Bochum, Germany
Nat Clin Pract Neurol 3:36-44. 2007..In this article, we review the current indications for IVIg treatment, address practical issues related to the use and costs of the drug, and summarize its mechanisms of action...
- The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profileMarinos C Dalakas
Neuromuscular Diseases Section, National Institute of Neurological Diseases and Stroke, National Institutes of Health, MSC 1382, Room 4N248, Building 10, 10 Center Drive, Bethesda, MD 20892 1382, USA
Pharmacol Ther 102:177-93. 2004..v.Ig with other immunosuppressive drugs...
- The involvement of Fc gamma receptor gene polymorphisms in Kawasaki diseaseM Biezeveld
Emma Children s Hospital, Academic Medical Centre AMC, University of Amsterdam, Amsterdam, The Netherlands
Clin Exp Immunol 147:106-11. 2007..Therapy consists of intravenous immunoglobulins (IVIG), leading to a decrease of complications to 5-16%...
- Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trialR van Koningsveld
Department of Neurology, Erasmus MC, Rotterdam, Netherlands
Lancet 363:192-6. 2004..Our aim was to assess whether methylprednisolone, when taken with IVIg, improves outcome when compared with IVIg alone...
- High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skinA Rutter
Department of Dermatology, University of Munster, Germany
J Am Acad Dermatol 44:1010-24. 2001Adjuvant high-dose intravenous immunoglobulins (IVIgs) are being used increasingly in a range of immune-mediated and autoimmune diseases...
- Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseasesS V Kaveri
INSERM U28, Paris, France
Clin Exp Immunol 86:192-8. 1991..This overview briefly discusses the current use of IVIg in human autoimmune diseases with a particular emphasis on the possible mechanisms by which IVIg could suppress pathological autoimmune responses...
- F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulinsMilan Basta
Neuronal Excitability Section, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
Nat Med 9:431-8. 2003..This binding could interfere with the role of C3a and C5a in inflammation...
- Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptorA Samuelsson
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
Science 291:484-6. 2001..Modulation of inhibitory signaling is thus a potent therapeutic strategy for attenuating autoantibody-triggered inflammatory diseases...
- Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapyDerin B Keskin
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA, USA
Cytokine 41:315-21. 2008..The conclusions from this limited number of patients, prospectively studied, would suggest that both CIST and IVIg therapies are similar in their ability to influence a panel of cytokines in patients with pemphigus vulgaris...
- Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg)Denis Glotz
Department of Nephrology, INSERM U 430, Hĵpital Européen Georges Pompidou, Paris, France
Am J Transplant 2:758-60. 2002..We have shown that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti-HLA antibodies...
- Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndromeBrigitte Buchwald
Department of Neurology, Julius Maximilians Universitat, Josef Schneider Strasse 11, 97080 Wurzburg, Germany
Ann Neurol 51:673-80. 2002..Therapeutic IVIg is capable of neutralizing neuromuscular blocking antibodies in GBS by a dose-dependent, antibody-mediated mechanism. This may, in part, explain its therapeutic efficacy...
- Kawasaki disease: etiology, pathogenesis, and treatmentKaryl S Barron
Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
Cleve Clin J Med 69:SII69-78. 2002
- Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki diseaseSungho Cha
Department of Pediatrics, College of Medicine, Kyunghee University Hospital, Dongdaemun Gu, Seoul, Korea
J Korean Med Sci 23:718-22. 2008..There is a need for a prospective study focused on baseline hepatobiliary parameters...
- Immune thrombocytopenic purpuraDouglas B Cines
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, USA
N Engl J Med 346:995-1008. 2002
- Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedsideG Zandman-Goddard
Department of Medicine C, Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Lupus 18:884-8. 2009..Hence, extractable IVIg that is directed to the specific pathogenic immunoglobulins will enable the more specific therapy for patients with lupus...
- The antiinflammatory activity of IgG: the intravenous IgG paradoxFalk Nimmerjahn
Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10021, USA
J Exp Med 204:11-5. 2007..Here we propose that these Fc-sialylated IgGs engage a unique receptor on macrophages that, in turn, leads to the upregulation of an inhibitory Fcgamma receptor (FcgammaR), thereby protecting against autoantibody-mediated pathology...
- High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 casesSonia Segura
Department of Dermatology, Hospital Clinic, Barcelona, Spain
J Am Acad Dermatol 56:960-7. 2007..Recently, high-dose intravenous immunoglobulin (IVIg) has been employed in selected cases, with excellent results in most of them...
- Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathyBjörn Tackenberg
Department of Neurology, Clinical Neuroimmunology Group, Philipps University, 35039 Marburg, Germany
Proc Natl Acad Sci U S A 106:4788-92. 2009....
- Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki diseaseHiroshi Tsujimoto
Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
Clin Immunol 103:161-8. 2002..As a result, the present study demonstrated a novel action in which high-dose IVIg therapy decreased the number of circulating neutrophils by accelerating their apoptosis in KD...
- Impairment of angiogenic activity in the serum from patients with coronary aneurysms due to Kawasaki diseaseKouji Higashi
Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
Circ J 71:1052-9. 2007..We hypothesized that serum activity to stimulate in vitro human umbilical vein endothelial cells (HUVEC) tube formation might be impaired in KD...
- The product: All intravenous immunoglobulins are not equivalentJerry Siegel
Department of Pharmacy, Ohio State University Medical Center, Columbus, Ohio 43210, USA
Pharmacotherapy 25:78S-84S. 2005..Convenience factors must be considered, for both the health care provider and the patient, without jeopardizing the more important features of the IGIV, such as tolerability and safety...
- Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boyMichel Lecendreux
J Sleep Res 12:347-8. 2003
- Mechanisms of action of intravenous immunoglobulinsAnne Baerenwaldt
Department of Biology, Institute of Genetics, University of Erlangen Nuremberg, Staudtstr 5, 91058 Erlangen, Germany
Expert Rev Clin Immunol 6:425-34. 2010..This review will discuss which molecular and cellular pathways might be involved in the anti-inflammatory activity of IVIg and for which types of autoimmune diseases they might be relevant...
- Early treatment with intravenous immunoglobulin in patients with Kawasaki diseaseShirley M L Tse
Division of Rheumatology and Cardiology, Department of Pediatrics, Hospital for Sick Children, Hospital for Sick Children Research Institute, University of Toronto, Ontario, Canada
J Pediatr 140:450-5. 2002....
- Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent waySven Jarius
Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany
Blood 109:4376-82. 2007....
- PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTERCAROL NESEL; Fiscal Year: 2012..k. ..
- PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTERCAROL NESEL; Fiscal Year: 2011..k. ..
- PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTERCAROL NESEL; Fiscal Year: 2010..k. ..
- PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTERCAROL NESEL; Fiscal Year: 2009..k...
- IMMUNOTHERAPY IN PEDIATRIC CEREBRAL MALARIATerrie Taylor; Fiscal Year: 1991..Children at highest risk of dying or developing brain damage can now be identified. A total 60 IVIG recipients and 60 controls will be required to detect a decrease in mortality from 50 percent to 25 percent...
- HIV-IG FOR PREVENTION OF VERTICAL TRANSMISSIONJAY JACKSON; Fiscal Year: 2003..2. Evaluate the differences in clinical progression to AIDS, the decline in CD4 counts, and survival at 2.5 years in the HIV-1 infected infants who received HIVIG or IVIG. ..
- Statistical Methods for Clinical Trials with Twin BirthsMichele Shaffer; Fiscal Year: 2007..Thus, the effects of trial design and analysis need to be quantified and taken into consideration for studies that involve singletons and twin births. [unreadable] [unreadable] [unreadable] [unreadable]..
- Naturally occurring T regulatory cells control airway hyperresponsivenessErwin Gelfand; Fiscal Year: 2008..abstract_text> ..
- MEKK2 Regulation of Mast Cell/T Cell Cytokine ProductionErwin Gelfand; Fiscal Year: 2003..The studies will also define MEKK2 and ERK5 as targets for drug discovery for the control of allergic inflammation. ..
- FcR Enhanced Ag Presentation--Induction Tumor ImmunityRaphael Clynes; Fiscal Year: 2006..3) Determine whether FcgammaR uptake enhances class I antigen presentation in human systems and specifically whether antibody-mediated T cell priming occurs in Trastuzumab-treated patients. ..
- PHAGOCYTOSIS IN PULMONARY ALVEOLAR MACROPHAGESRaphael Clynes; Fiscal Year: 2009....
- Pathogenic Role of Islet Cell Abs in Autoimmune DiabetesRaphael A Clynes; Fiscal Year: 2010..We propose in Aim 3 to extend this work to test relevance to the antibody-mediated cross-presentation of insulin, an antigen of singular importance to diabetes. ..
- OCULAR PEMPHIGOID--MECHANISM OF PATHOGENESISA Ahmed; Fiscal Year: 2001..The immediate clinical impact of this research will be the generation and availability of highly specific and sensitive serological laboratory test for the early diagnosis of OCP. ..
- Fibrogenic factors in ocular cicatricial pemphigoidA Ahmed; Fiscal Year: 2004..The studies have significant therapeutic potential. The identified molecules or portion of processes that mediate could be blocked or arrested, and this may result in cessation of disease progression and, prevention of blindness. ..
- Interleukin 1alpha polymorphism and Alzheimer's diseaseYansheng Du; Fiscal Year: 2004..abstract_text> ..
- MR PREDICTORS OF RESPONSE TO HAART IN HIV DEMENTIAJoseph Berger; Fiscal Year: 2004..It will also open novel avenues for exploring the differential sensitivities of these pathways to HAART, and suggest unique therapeutic options. ..
- JCV Virus Expression in Oropharynx and HIVJoseph Berger; Fiscal Year: 2004..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
- PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONSJean Claude Bystryn; Fiscal Year: 2005..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
- ICAM1 gene inactivation protects against ischemic injuryRobert Montgomery; Fiscal Year: 2006..This work has important implications for the selective inactivation of gene function in allografts through ex vivo gene transfer. ..
- 2003 CIS Summer SchoolCharlotte Cunningham Rundles; Fiscal Year: 2003..The participants will be drawn from training programs, hospitals and institutions that are in North, Central or South America. Only fellows from the United States will receive funding made possible through the NIH grant. ..
- VLA4 IN CTL MEDIATED ISLET ALLOGRAFT REJECTIONMark Stegall; Fiscal Year: 2001..The approach may lead to novel forms of immune suppression that may benefit not only islet transplantation, but also other types of organ allografts. ..
- NEUROSCIENCE OF HIV CONFERENCEJoseph Berger; Fiscal Year: 2002..Dr. Brian Wigdahl, international co-chair of the ISNV, is a co-investigator on this grant. ..
- POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMAJean Claude Bystryn; Fiscal Year: 2004..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
- Primary Immune Deficiency Consortium ConferenceCharlotte Cunningham Rundles; Fiscal Year: 2008..Principle topics will focus on: Diagnosis of Immunodeficiency; Genetics, Immune Reconstruction, and the Use of Standard and Novel Therapies. ..
- SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMAJean Claude Bystryn; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Primary Immunne Deficiency Consortium ConferenceCharlotte Cunningham Rundles; Fiscal Year: 2005..Principle topics will focus on: Antibody Deficiency; Combined Immune Defects; Neutrophil Disorders; Laboratory Evaluation of Primary Immunodeficiency; Immune Reconstiution, and the Use of Standard and Novel Therapies. ..
- HIV Neuroprotection WorkshopJoseph Berger; Fiscal Year: 2004..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
- 2002 Summer School in Primary Immunodeficiency DisordersCharlotte Cunningham Rundles; Fiscal Year: 2002..Fellows participating in the course will be reimbursed for their travel expenses. No registration fee will be charged for the fellows participating in the program. ..
- Bone Marrow Angioblasts For Cardiac RegenerationSilviu Itescu; Fiscal Year: 2004....
- MECHANISMS OF IL-2 IMMUNE ENHANCEMENT IN HUMANSCharlotte Cunningham Rundles; Fiscal Year: 2001..Thus, this application will focus on the cellular and molecular mechanisms by which IL-2 reconstitutes T cell immunity in this model system. ..
- Reconstitution of Protective CMV Immunity and Immune Regulation After HAARTAdriana Weinberg; Fiscal Year: 2008..These analyses will define the role of TREG in the inadequate CMV immune reconstitution of HAART recipients. [unreadable] [unreadable] [unreadable] [unreadable]..
- Proteolytic Antibody HIVcidesSudhir Paul; Fiscal Year: 2007..These studies may identify proteolytic antibodies suitable for further development as a topical HIVcide. [unreadable] [unreadable] [unreadable]..
- Oral Delivery of DNA VaccinesFRANK ORSON; Fiscal Year: 2003....
- Protection of Mice From Lethal Alphavirus EncephalitisDavid N Irani; Fiscal Year: 2010....
- ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCIDDennis Burton; Fiscal Year: 2001..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
- PATHOGENESIS OF THROMBOCYTOPENIAS OF NEONATESRobert Christensen; Fiscal Year: 2002..This approach is essential to improve the care of the large number of NICU patients affected with these two common varieties of thrombocytopenia. ..
- TRAINING GRANT IN MOLECULAR CARDIOLOGYMark Entman; Fiscal Year: 2008..This integrated design has consistently proven to be effective in providing successful independent and competitive investigators in molecular biology of cardiovascular medicine. ..
- RECOMBINANT SINGLE DOMAIN & HYBRID PEPTIDASE ANTIBODIESSudhir Paul; Fiscal Year: 2002....
- Genetic Markers and gene expression in Kawasaki DiseaseJane C Burns; Fiscal Year: 2010..This project will build on previous work to understand the genetic basis for susceptibility to KD and its complications, which will lead to new insights into therapeutics and disease prevention. ..
- Brain Atrophy/Diffusion Tensor Study/Multiple SclerosisRobert Fox; Fiscal Year: 2008..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..
- Detection of Biofilm Bacteria using GloBacRobin Patel; Fiscal Year: 2008..The goal of the proposed studies is to develop a rapid test for detection of bacteria on artificial joints that can be used in the operating room to diagnose infected artificial joints. [unreadable] [unreadable] [unreadable]..
- AAV Gene Therapy for Alzheimer's DiseaseDavid Morgan; Fiscal Year: 2009..The outcome of these studies will, hopefully, be a novel gene therapeutic approach to dismantle the catastrophe of Alzheimer's dementia. ..
- Novel Strategies for Y pestis ImmunotherapyJeffrey Ravetch; Fiscal Year: 2003..pestis mutants defective in virulence. This approach will thus permit the evaluation of the interaction of the pathogen with adaptive immune pathways by bypassing the effects on innate responses. ..
- Development of Autoimmunity During Puberty in SLEKATHLEEN O NEIL; Fiscal Year: 2007..The data from this study will allow us to estimate sample size and perform power analyses for a larger study utilizing all CARRA centers. [unreadable] [unreadable]..
- Pharmacogenetics in Tourette SyndromHarvey Singer; Fiscal Year: 2004..The identification of genetic polymorphisms that are associated with clinical disease or treatment success, has obvious benefits. ..
- 8th International Kawasaki Disease SymposiumJane Burns; Fiscal Year: 2005....
- High dose erythropoietin for neonates with asphyxiaRobert Christensen; Fiscal Year: 2004..To aid the design of a subsequent Phase III trial, neurodevelopmental outcome will be measured in the EIP program clinics at six and 12 months or life. ..
- Molecular Characterization of a Human DysfibrinogenVERONICA FLOOD; Fiscal Year: 2005..This study will provide valuable information about the structural and functional behavior of this dysfibrinogen and will ultimately improve understanding of clot formation and the process of hemostasis. ..
- Robotic Preparation of cDNA Single CellsWilliam Cleveland; Fiscal Year: 2006..In summary, we believe that an instrument which couples multidimensional microscopy with DNA array technology will be a spectacular tool that will be useful to many laboratories. ..
- PTS1 Regulation of Brain Met Enk Levels in AlcoholismWilliam Banks; Fiscal Year: 2004..abstract_text> ..
- VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIESDennis Burton; Fiscal Year: 2004..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
- Pregnancy and the Modulation of Multiple SclerosisAnnette Langer Gould; Fiscal Year: 2006..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
- Opiate Addiction and HIV-1 Induced Release of CytokinesWilliam Banks; Fiscal Year: 2006....
- Endotoxin-induced Uveitis RevisitedJames T Rosenbaum; Fiscal Year: 2010..Future studies can buil d on these observations to test anti-inflammtory molecules induced by endotoxin as these molecules are potentially useful in the treatment of uveitis and other inflammations. ..
- STUDY OF FC RECEPTOR GENES: MACROPHAGES AND LYMPHOCYTESJeffrey Ravetch; Fiscal Year: 2007..unreadable]..
- BAYESIAN METHODS IN BIOSTATISTICSJoel Greenhouse; Fiscal Year: 2002..Yet, despite great progress in the use of these models, fundamental issues remain, as we explain below, this is the main motivation of our work. ..
- beta-Amyloid Antibodies with Specific Proteolytic ActivitySudhir Paul; Fiscal Year: 2008..Proteolytic anti-Abeta Abs capable of preventing the deposition of Abeta and cognitive decline would be candidates for passive immunotherapy of humans with AD. ..
- INNATE AND Ag-ADAPTED CHEMICALLY REACTIVE ANTIBODIESSudhir Paul; Fiscal Year: 2003..Successful execution of this project will provide insight to the genesis of chemically reactive Abs and potentially validate the use CRAs for inhibition and induction of antigen-specific catalytic Abs. ..
- gp120 covalent analogs as candidate HIV vaccinesSudhir Paul; Fiscal Year: 2008..Novel vaccination strategies and HIV-1 neutralizing Abs will emerge from these studies if the physiological barriers to catalytic Ab synthesis can be bypassed. [unreadable] [unreadable]..
- CATALYTIC ANTIBODIES FOR TUMOR IMMUNOTHERAPYSudhir Paul; Fiscal Year: 2001..The investigators expect the proposed studies to generate catalytic Fv constructs capable of permanent and efficient inactivation of EGFR, and to establish the validity of using catalytic Abs for tumor immunotherapy. ..
- BEHAVIORAL INTERVENTION FOR CONGENITAL CMV DISEASEStuart Adler; Fiscal Year: 2001..The results of this trial will determine the effectiveness of behavioral intervention and the motivation necessary to adhere to recommendations and prevent child-to-mother transmission of CMV. ..
- 10th International CMV WorkshopStuart Adler; Fiscal Year: 2005..The purpose is to keep everybody up to date and current about what's going on in all areas and stimulate new research projects and collaborations. We anticipate between 300 and 500 attendees. ..
- EPIDEMIOLOGY OF CMVStuart Adler; Fiscal Year: 2007..The results of this study will establish if immunization of mothers against CMV infection is possible. ..
- Prevention of Cytomegalovirus InfectionStuart Adler; Fiscal Year: 2007..The results of this study will establish if prevention of CMV infections is possible. [unreadable] [unreadable]..